 An independent data safety monitoring board DSMB has conducted the first of two planned Sample Size Reestimations SSR1 of Phase 3 URIROX-2 Trial of Allena Pharmaceuticals Incs NASDAQ: ALNA reloxaliase for enteric hyperoxaluria. Hyperoxaluria increases the risk of. 